The board of PharmNovo AB is pleased to announce that former VP Business Development Per von Mentzer assumed the position as new Chief Executive Officer of PharmNovo AB effective May 2020.
“Given his general management and commercial experience, we are confident that Per is the right person to lead us through the next phases of development,” says Chairman of the Board Göran Lerenius, who continues:
“Through this appointment PharmNovo is strengthening the organisation on both the scientific and commercial sides, whilst maintaining full focus on the continued pre-clinical development.
The company’s founder and former CEO, Bengt von Mentzer, remains critical to PharmNovo´s business activities and will now focus even more of his time and efforts on the PN6047 development and the upcoming Regulatory Toxicology programme.
At the Extraordinary General Meeting held in May at Medicon Village, Lund, Sweden, Chairman of the Board Göran Lerenius thanked Bengt for founding the company and for leading it successfully over many years.
22 MSEK new funding
PharmNovo has completed a new share issue of 22 million SEK with the Sciety investment syndicate as the lead investor.
Read more →Research coaction
As a result of our publication in JPET with University of Bristol, contact was established with Prof. Amynah Pradhan at the University of Illinois, Chicago.
Read more →New CEO appointed
The board of PharmNovo AB is pleased to announce that former VP Business Development Per von Mentzer assumed the position as new Chief Executive Officer of PharmNovo AB effective May 2020.
Read more →JPET approves PN6047
In collaboration with our research partners at the University of Bristol, we have had a manuscript detailing the results of our preclinical studies of PN6047 accepted for publication in the highly cited Journal of Experimental Pharmacology and Therapeutics (JPET), the official journal of the American Society for Pharmacology and Experimental Therapeutics (ASPET).
Read more →
